Role of Multislice CT in Diagnosis of Inflammatory Bowel Disease
Role Of Computed Tomography Enterography in Diagnosis of Inflammatory Bowel Disease
1 other identifier
observational
30
0 countries
N/A
Brief Summary
Aim of the work: To evaluate the role of CT in diagnosis of IBD
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2018
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 13, 2018
CompletedFirst Posted
Study publicly available on registry
February 19, 2018
CompletedStudy Start
First participant enrolled
October 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2019
CompletedFebruary 20, 2018
February 1, 2018
11 months
February 13, 2018
February 17, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Diagnosis of inflammatory bowel disease by MSCT enterography
detect the early complication of the disease: fistula, stricture, fibofatty changes by enterography
baseline
Interventions
Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
Eligibility Criteria
* Number of 30 Patients with inflammatory bowel disease will be included in the study. * CT scans are typically performed for IBD evaluation following administration of both oral and IV contrast to detect bowel wall abnormalities and abnormal enhancement\[6\] * Conventional CT uses positive enteral contrast agents, usually water soluble containing solutions, which increase the attenuation of the bowel lumen and of bowel wall abnormalities and extraluminal fluid collections.
You may qualify if:
- Patient in the age group between 15\&40 and another age group between 50\&80 with inflammatory bowel disease.
You may not qualify if:
- Patients with any general contraindication to Radiation of CT especially pregnant women.
- Patients with any general contraindication to contrast, impaired renal function \& hypersensitivity.
- Patients of the age group below 15 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17. doi: 10.1053/j.gastro.2004.01.063.
PMID: 15168363RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
shreef abd, prof
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle investigator
Study Record Dates
First Submitted
February 13, 2018
First Posted
February 19, 2018
Study Start
October 1, 2018
Primary Completion
September 1, 2019
Study Completion
October 1, 2019
Last Updated
February 20, 2018
Record last verified: 2018-02
Data Sharing
- IPD Sharing
- Will not share